The safety profile of denosumab in oncology beyond the safety of denosumab as an anti-osteoporotic agent: still more to learn
Sign Up to like & getrecommendations! Published in 2020 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2021.1861246
Abstract: ABSTRACT Introduction Initially endorsed as an antiosteoporotic agent, denosumab ‒ human monoclonal antibody inhibiting the receptor activator of nuclear factor kappa-B ligand (RANKL)‒ has currently shown an anticancer potential, rationalizing its exploitation in oncology. A… read more here.
Keywords: agent; safety profile; safety; oncology ... See more keywords